Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 2

Conditions

Leukemia, Myeloid, Acute 3Glioblastoma 3Gliosarcoma 2Brain Neoplasms 2Prostatic Neoplasms 1Pain 1Oligodendroglioma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Glioma 1Carcinoma, Renal Cell 1Astrocytoma 1

Interventions

Temozolomide 162Radiosurgery 115Radiotherapy 100Bevacizumab 96Magnetic Resonance Spectroscopy 65Carboplatin 48Etoposide 34pembrolizumab 33Surgical Procedures, Operative 33Irinotecan 33Nivolumab 32Cyclophosphamide 32Erlotinib Hydrochloride 31Radiation 30Carmustine 28Lomustine 25Cisplatin 25Trastuzumab 23Ipilimumab 23Filgrastim 23Vincristine 20Mental Status and Dementia Tests 20Aminolevulinic Acid 19Topotecan 18Pemetrexed 18Capecitabine 18Specimen Handling 17Sorafenib 15Radiotherapy, Intensity-Modulated 15Imatinib Mesylate 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Brain Neoplasms × tandutinib × Clear all
NCT00379080 2017-04-07

Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma

National Cancer Institute (NCI)

Phase 1/2 Completed
60 enrolled 22 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00667394 2015-11-05

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
42 enrolled 11 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡